The drug, called memantine, could enter clinical trials to determine its effectiveness in humans.

A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.

Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.

Two clinical trial participants—one with β-thalassemia and one with sickle cell disease—appeared to benefit from the gene-editing treatments with minimal side effects, according to the companies.

The US Food and Drug Administration halts a study by Solid Biosciences after a patient experiences severe side effects following treatment.

Oligomannate, derived from a compound in seaweed, suppresses neural inflammation caused by gut bacteria in mice.

Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

The small molecule is effective in tomato and wheat in laboratory trials, but its scalability and applicability to real-world agriculture remains to be seen.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.